Active, not recruitingNCT04157322
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
Studying Genetic intestinal disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Chicago
- Principal Investigator
- Bruce Bissonnette, MDUniversity of Chicago
- Intervention
- prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study(diagnostic_test)
- Enrollment
- 55 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (1)
- The University of Chicago, Chicago, Illinois, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04157322 on ClinicalTrials.govOther trials for Genetic intestinal disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06177938Lactobreath: A Study to Diagnose Lactose Intolerance Using Breath MarkersETH Zurich
- RECRUITINGNANCT05398380Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational ResearchHospital Vall d'Hebron
- ACTIVE NOT RECRUITINGNANCT07555639An Integrated Genomic Approach to Assess Genetic Risk and Drug SensitivityFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06096688Discovering New Targets for Colorectal and Endometrial Cancer Risk ReductionWeill Medical College of Cornell University
- ACTIVE NOT RECRUITINGNCT04087239The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT StudyUniversity of Zimbabwe